Literature DB >> 17151818

Inflammatory markers in a 2-year follow-up of coronary artery disease.

Katarzyna Mizia-Stec1, Zbigniew Gasior, Barbara Zahorska-Markiewicz, Michał Holecki, Paweł Kumor.   

Abstract

Our study was designed in an attempt to determine the dynamics of changes in serum tumor necrosis factor (TNF)-alpha, soluble forms of its receptors (sTNFR 1, sTNFR 2), and adhesion molecules (sE-selectin, sP-selectin, sVCAM-1, sICAM-1) over a 2-year follow-up of patients with coronary artery disease (CAD). The study involved 70 patients with stable CAD (stable angina class II/III according to the Canadian Cardiovascular Society) and 20 apparently healthy subjects. Over the follow-up period a marked attenuation of angina (P<0.001) was observed. Interventional treatment (percutaneous coronary intervention, coronary artery bypass grafting) was used in 53 CAD patients. Laboratory analysis revealed a significant decrease of serum TNF-alpha and sTNFR1 at 2 years (TNF-alpha: 12.1+/-0.7 pg/ml; sTNFR 1: 1306+/-46 pg/ml) as compared to baseline levels (16.5+/-0.7 pg/ml, P=0.030; 1551+/-82 pg/ml, P=0.048, respectively). The levels of sP-selectin (159+/-7 vs 201+/-14 ng/ml, P<0.01) and sICAM-1 (133+/-4 vs 153+/-6 ng/ml, P<0.05) were found to be significantly increased as compared to the baseline. Interventional procedures resulted in suppression of both cytokine (TNF-alpha, sTNFR 2) and adhesion molecule (sE-selectin, sP-selectin) activation in the CAD group. The baseline and post-follow-up TNF-alpha and sTNFR 1 levels showed persistent elevation in CAD patients as compared to the controls (9.0, 956.3 pg/ml, respectively; P<0.01). There were no differences between baseline and final cytokines and adhesion molecules in healthy subjects. The course of CAD as modified by a clinically effective therapy is characterized by changes of immune markers activation. Revascularization seems to be an important factor suppressing both cytokine and adhesion molecule activation in CAD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151818     DOI: 10.1007/s00380-006-0910-8

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  28 in total

1.  Soluble P-selectin and the risk of future cardiovascular events.

Authors:  P M Ridker; J E Buring; N Rifai
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

2.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.

Authors:  P M Ridker; N Rifai; M Pfeffer; F Sacks; S Lepage; E Braunwald
Journal:  Circulation       Date:  2000-05-09       Impact factor: 29.690

3.  Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study.

Authors:  X Q Zhao; C Yuan; T S Hatsukami; E H Frechette; X J Kang; K R Maravilla; B G Brown
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

4.  Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease.

Authors:  K Bachmaier; C Pummerer; I Kozieradzki; K Pfeffer; T W Mak; N Neu; J M Penninger
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

5.  Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis.

Authors:  Imo E Hoefer; Niels van Royen; John E Rectenwald; Elizabeth J Bray; Zaher Abouhamze; Lyle L Moldawer; Michiel Voskuil; Jan J Piek; Ivo R Buschmann; C Keith Ozaki
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

6.  Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease.

Authors:  A D Simon; S Yazdani; W Wang; A Schwartz; L E Rabbani
Journal:  Clin Cardiol       Date:  2001-03       Impact factor: 2.882

Review 7.  The selectins: vascular adhesion molecules.

Authors:  T F Tedder; D A Steeber; A Chen; P Engel
Journal:  FASEB J       Date:  1995-07       Impact factor: 5.191

8.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

9.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).

Authors:  G Torre-Amione; S Kapadia; C Benedict; H Oral; J B Young; D L Mann
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

10.  The role of inflammation markers in triggering acute coronary events.

Authors:  Mehmet Tokaç; Ali Ozeren; Murad Aktan; Bülent B Altunkeser; Kurtuluş Ozdemir; Akif Düzenli; Hasan Gök
Journal:  Heart Vessels       Date:  2003-09       Impact factor: 2.037

View more
  6 in total

1.  Carotid intima-media thickness in pre- and postmenopausal women with suspected coronary artery disease.

Authors:  Anna Kablak-Ziembicka; Tadeusz Przewlocki; Wieslawa Tracz; Piotr Pieniazek; Piotr Musialek; Andrzej Sokolowski; Rafal Drwila; Daniel Rzeznik
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

2.  Abdominal obesity and inflammation predicts hypertension among prehypertensive men and women: the ATTICA Study.

Authors:  Christos Pitsavos; Christina Chrysohoou; Demosthenes B Panagiotakos; Yannis Lentzas; Christodoulos Stefanadis
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

3.  Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention.

Authors:  Nihat Ozer; Burak Tangurek; Fatih Firat; Songul Ozer; Zeynep Tartan; Recep Ozturk; Batuhan Ozay; Figen Ciloglu; Hale Yilmaz; Nese Cam
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

4.  Presence of irregularity in region between -1115 and -784 nt in P1 promoter of insulin-like growth factor-1 gene may indicate beneficial effect on coronary arteries in a group of patients with stable angina: preliminary data.

Authors:  Pawel Burchardt; Witold Nowak; Anna Gozdzicka-Jozefiak; Rafal Link; Tomasz Grotowski; Anna Wisniecka; Tomasz Siminiak
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

5.  Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms.

Authors:  Jaroslav Meluzín; Anna Vasků; Vladimír Kincl; Roman Panovský; Tat'ána Srámková
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

6.  10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial Substudy.

Authors:  Axel C Carlsson; Toralph Ruge; Erik Kjøller; Jørgen Hilden; Hans Jørn Kolmos; Ahmad Sajadieh; Jens Kastrup; Gorm Boje Jensen; Anders Larsson; Christoph Nowak; Janus Christian Jakobsen; Per Winkel; Christian Gluud; Johan Ärnlöv
Journal:  J Am Heart Assoc       Date:  2018-04-23       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.